NASDAQ:CNTX Context Therapeutics Q3 2025 Earnings Report $0.31 0.00 (-1.49%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.31 +0.00 (+1.39%) As of 10/2/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Context Therapeutics EPS ResultsActual EPS-$0.10Consensus EPS -$0.09Beat/MissMissed by -$0.01One Year Ago EPSN/AContext Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AContext Therapeutics Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time7:00AM ETUpcoming EarningsContext Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Context Therapeutics Earnings HeadlinesContext Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comContext Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 3 at 1:00 AM | Stansberry Research (Ad)Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 for Solid TumorsSeptember 9, 2026 | quiverquant.comQContext Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202September 9, 2026 | globenewswire.comLifeSci Capital downgrades Context Therapeutics (CNTX) to a HoldAugust 10, 2026 | theglobeandmail.comSee More Context Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email. Email Address About Context TherapeuticsContext Therapeutics (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company focused on developing targeted and immune-based treatments for solid tumors, with an emphasis on cancers that have limited treatment options. The company is headquartered in Philadelphia and conducts development activities through collaborations and clinical research networks. Its lead investigational program is CTIM-76, a bispecific antibody designed to recognize Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. By bringing T cells into proximity with CLDN6-expressing cancer cells, the treatment is intended to stimulate an immune response against tumors. CTIM-76 is being evaluated in early-stage clinical research for patients with advanced solid tumors. Context Therapeutics was founded in 2015 and became a publicly traded company in 2021. The company previously pursued therapies for hormone-responsive cancers, including the progesterone-receptor antagonist onapristone, before shifting its primary focus toward CLDN6-directed cancer immunotherapies. Context Therapeutics is led by Chief Executive Officer Martin Lehr.View Context Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
